Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04925713 · ClinicalTrials.gov registry record · Phase 1
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
A Phase 1 study, sponsored by TuHURA Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04925713 is a Phase 1 study that has completed, run by TuHURA Biosciences. The registered enrollment target is 5 participants.
The verdict
NCT04925713, a Phase 1 study, has completed, sponsored by TuHURA Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..
Interventions
- BIOLOGICAL IFx-Hu2.0
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-06-10 |
| Est. Completion | 2022-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04925713
The ClinicalTrials.gov registry entry for NCT04925713 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is TuHURA Biosciences, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IFx-Hu2.0 is the first listed.
NCT04925713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04925713 about?
NCT04925713 is a clinical study titled "IFx-Hu2.0 for the Treatment of Patients With Skin Cancer". One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed adverse events..
What is the current status of trial NCT04925713?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-06-10. Estimated completion is 2022-03-10.
What interventions are being tested in trial NCT04925713?
The interventions under investigation include: IFx-Hu2.0 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04925713?
This trial is sponsored by TuHURA Biosciences, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.